Your browser version may not work well with NCBI's Web applications. More information here...
1: Yonsei Med J. 2004 Oct 31;45(5):885-90. Links

The role of estrogen receptor, progesterone receptor and p53 in development of stress urinary incontinence.

Bai SW, Jung YW, Kwon HS, Yoon JM, Shin JS, Kim SK, Park KH, Park JH.

Department of Obstetrics and Gynecology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. swbai@yumc.yonsei.ac.kr

Recent studies have been reported the roles of the estrogen receptor (ER), progesterone receptor (PR) and p53 in the development of a pelvic organ prolapse (POP). The pathogenesis of stress urinary incontinence (SUI) is related to that of POP in the weakness of pelvic support. Therefore, this study was carried out to assess the relationship between ER, PR, p53 and the development of SUI, and to elucidate the biomolecular pathophysiology of SUI. The periurethral fascia was obtained from 6 menopausal patients diagnosed with SUI and 10 menopausal patients without SUI who visited the Department of Obstetrics and Gynecology, Severance Hospital, Seoul, Korea. The relative ER, PR and p53 protein levels in the periurethral fascia were obtained by western blot analysis and densitometry. A Mann-Whitney U test was used for statistical analysis (p < 0.05). The mean age (+/- SD) of the 16 patients was 59.0 +/- 5.5 years (range, 50-74 years). The mean body mass index was 25.2 +/- 2.7 kg/m2 (21.8 - 30.8) and the average number of vaginal deliveries was 2.8 +/- 1.9 (1.0 - 9.0). The ER level (0.33 +/- 0.17 vs. 1.86 +/- 0.83, p= 0.02) and the p53 level (1.25 +/- 0.67 vs. 4.71 +/- 2.40, p= 0.01) were lower in the experimental group. However, the PR level of the two groups were similar (0.64 +/- 0.13 vs. 0.48 +/- 0.33, p=0.56). The p53 and ER levels were significant lower in the study group. This suggests that p53 and ER might be important factors in the development of SUI. Further prospective studies about the association of ER, p53 and SUI will be needed to elucidate the molecular pathogenesis of SUI.

PMID: 15515200 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Estrogen (Cenestin® , Enjuvia® , Estrace® , ...)

    Estrogen is used to treat hot flushes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen...

  • Progesterone (Prometrium® )

    Progesterone is used as a part of hormone replacement therapy in women who have passed menopause (the change of life) and have not had a hysterectomy (surgery to remove the uterus). Hormone replacement therapy usually in...

  • Estrogen Vaginal (Estrace® , Estring® , Femring® , ...)

    Vaginal estrogen is used to treat vaginal dryness, itching, and burning; painful or difficult urination; and sudden need to urinate immediately in women who are experiencing or have experienced menopause (change of life;...

  • Source: AHFS Consumer Medication Information